Zhang, H., Schneider, S. E., Bray, B. L., Friedrich, P. E., Tvermoes, N. A., Mader, C. J., … Wring, S. A. (2008). Process Development of TRI-999, a Fatty-Acid-Modified HIV Fusion Inhibitory Peptide. Organic Process Research & Development, 12(1), 101–110. https://doi.org/10.1021/op7002198

Zhang, Huyi, Stephen E. Schneider, Brian L. Bray, Paul E. Friedrich, Nicolai A. Tvermoes, Catherine J. Mader, Sheila R. Whight, et al. “Process Development of TRI-999, a Fatty-Acid-Modified HIV Fusion Inhibitory Peptide.” Organic Process Research & Development 12, no. 1 (January 1, 2008): 101–10. https://doi.org/10.1021/op7002198.

Zhang H, Schneider SE, Bray BL, Friedrich PE, Tvermoes NA, Mader CJ, et al. Process Development of TRI-999, a Fatty-Acid-Modified HIV Fusion Inhibitory Peptide. Organic Process Research & Development. 2008 Jan 1;12(1):101–10.

Zhang, Huyi, et al. “Process Development of TRI-999, a Fatty-Acid-Modified HIV Fusion Inhibitory Peptide.” Organic Process Research & Development, vol. 12, no. 1, American Chemical Society (ACS), Jan. 2008, pp. 101–10. Crossref, doi:10.1021/op7002198.

Zhang H, Schneider SE, Bray BL, Friedrich PE, Tvermoes NA, Mader CJ, Whight SR, Niemi TE, Silinski P, Picking T, Warren M, Wring SA. Process Development of TRI-999, a Fatty-Acid-Modified HIV Fusion Inhibitory Peptide. Organic Process Research & Development. American Chemical Society (ACS); 2008 Jan 1;12(1):101–110.